Defining A Novel Mechanism Of Control Of Host Functions By Human Cytomegalovirus That Enhances Viral Pathogenesis
Funder
National Health and Medical Research Council
Funding Amount
$616,518.00
Summary
Human cytomegalovirus (HCMV) remains a significant human pathogen which causes serious and often life-threatening disease in immunosuppressed people such as bone marrow and solid organ transplant patients and in unborn babies infected during pregnancy. This project will define how HCMV controls host defences by actively modifying the cells it infects to create an environment favourable to continued viral infection and disease.
Defining A Virally-encoded Molecular Switch Between Productive And Latent Phases Of Human Cytomegalovirus Infection.
Funder
National Health and Medical Research Council
Funding Amount
$337,614.00
Summary
Human cytomegalovirus (HCMV) is a significant human pathogen which causes serious disease in immunosuppressed people such as bone marrow and solid organ transplant patients. HCMV has the capacity to switch between an active and a dormant state, enabling this virus to remain within the human host, where it can emerge years later to cause disease in immunosuppressed people. This project will define how HCMV controls the switch between active and dormant phases of infection.
Prophylactic Vaccine To Prevent Cytomegalovirus Disease
Funder
National Health and Medical Research Council
Funding Amount
$436,360.00
Summary
This project is aiming to develop a prophylactic vaccine against a common herpesvirus which has been linked to the birth defects in new born babies and significant morbidity and mortality in transplant patients. In this project we are testing a novel nanoparticle-based vaccine formulation which stimulates the immune system with single injection and the immunity induced is sustained for long-term.
The Balance Of Signals Received By NK Cells Is Modulated By Viruses As A Mean Of Immune Escape.
Funder
National Health and Medical Research Council
Funding Amount
$583,175.00
Summary
Cytomegalovirus (CMV) affects about 60% of the population in Australia. Infection is partially controlled by the immune system but CMV is never eliminated and people remain carriers for the rest of their life. Reactivation of CMV in healthy individuals is usually asymptomatic, but it causes severe diseases in people with immune deficiencies. We seek to discover the mechanisms used by CMV to escape immune surveillance, in order to gain insights into the development of improved antiviral therapies
The Pathogenesis And Prevention Of Congenital Cytomegalovirus Disease
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
Cytomegalovirus (CMV) infection during pregnancy can have devastating effects on the developing baby, causing life-long disease and fetal death. Despite CMV being the most common infectious cause of fetal injury, there are significant gaps in our understanding of this congenital disease and no therapeutics available for use during pregnancy. This study will investigate the genetic molecular mechanisms by which CMV causes fetal injury and develop interventional therapies to reduce disease.
What Is The Profile, Burden And Consequences Of Cerebral Palsy (CP) Due To Congenital Cytomegalovirus (CMV) Infection?
Funder
National Health and Medical Research Council
Funding Amount
$87,130.00
Summary
Cytomegalovirus (CMV) is a virus that can be transmitted from mother to the unborn child. It is a potentially preventable cause of cerebral palsy (CP). The incidence of CP due to CMV remains unclear in Australia as screening for CMV is not routinely performed in the newborn. Our preliminary data suggests that severe CP is strongly associated with CMV. Here we will use link recorded data and test CMV in newborn screening cards to determine the burden and profile of CP due to congenital CMV in Aus ....Cytomegalovirus (CMV) is a virus that can be transmitted from mother to the unborn child. It is a potentially preventable cause of cerebral palsy (CP). The incidence of CP due to CMV remains unclear in Australia as screening for CMV is not routinely performed in the newborn. Our preliminary data suggests that severe CP is strongly associated with CMV. Here we will use link recorded data and test CMV in newborn screening cards to determine the burden and profile of CP due to congenital CMV in Australia.Read moreRead less
Individualizing Cytomegalovirus Preventative Strategies Following Solid Organ Transplantation: A Precision Medicine Approach
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Cytomegalovirus (CMV) infection is a significant contributor to poor outcomes following solid organ transplantation. Current preventative strategies are somewhat effective but treat groups of patients similarly rather than targeting the individual, so many patients are treated unnecessarily & breakthrough disease still occurs. We propose a program of research directed towards individualizing CMV prevention strategies in solid organ transplant recipients, incorporating new diagnostic tests.
Human Cytomegalovirus Encoded Control Of The Latent Phase Of Infection
Funder
National Health and Medical Research Council
Funding Amount
$639,871.00
Summary
Human cytomegalovirus has the ability to hide in the body of a person throughout their life time without it making them ill but the virus can awaken (reactivate) from this latent state and produce new virus. In immunosuppressed people such as transplant patients this reactivation causes significant problems, even death, yet this latency remains poorly understood. This project will help us to understand how the virus can hide successfully from the immune system in a latent form in the human host.
Whole-of-population CRISPR Point-of-care Testing For Congenital Cytomegalovirus To Prevent Hearing And Neurodevelopment Disabilities Through A Public Health Approach
Funder
National Health and Medical Research Council
Funding Amount
$2,058,920.00
Summary
Congenital cytomegalovirus infection (cCMV) is the major infective cause of deafness and brain disability, both of which are potentially reversible with early treatment. Currently, there is no screening at birth, and cCMV is diagnosed too late for treatment. Our team will test and validate CRISPR, a new and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise how cCMV is detected, make treatment more accessible and pave way to lower rates of deafness and cerebral palsy.